Key Highlights

  • Third-quarter 2026 net loss was USD 8.1 million, or USD 1.94 per share.
  • Research and development expenses were USD 5.6 million, against USD 6.4 million.
  • Cash and cash equivalents were USD 5 million at September 30, 2026.
  • Updated data showed an 86% response rate in seven BTK-naive PCNSL patients.

Curis (NASDAQ:CRIS) reported third-quarter 2026 loss per share of USD 1.94, against an estimate of USD 2.01. The clinical-stage biotechnology company reported no revenue. Its lead program is emavusertib, being studied in non-Hodgkin lymphoma subtypes.

Chief Executive Officer James Dentzer said the company continues to make progress in its TakeAim Lymphoma study in primary CNS lymphoma, or PCNSL, a registrational study of emavusertib in combination with ibrutinib in relapsed or refractory patients.

Clinical Update

Management reported updated data for seven BTK-inhibitor-naive patients and 39 salvage-line patients, whose disease had progressed during BTK inhibitor treatment. In the BTK-naive group, the data show an 86% response rate, with six of seven patients responding. Management noted that published studies of BTK inhibitors in PCNSL have generally shown response rates of 39% to 67%.

In salvage-line patients, the data show a 26% response rate, with 10 of 39 patients responding to emavusertib plus a BTK inhibitor after progressing on BTK inhibitor monotherapy. Management said the data support the potential for Accelerated Approval submissions in the United States and Europe, and that it looks to complete full enrollment in the registrational study in 2027, with a filing in 2028. In response to a question, management said its hurdle is generally a 20% objective response rate.

Management also discussed its second lymphoma study, in chronic lymphocytic leukemia, which was initiated earlier this year. It said the approach adds emavusertib to a BTK inhibitor regimen, with the BTK inhibitor blocking the BCR pathway and emavusertib blocking the TLR pathway.

Financial Results

Curis reported a net loss of USD 8.1 million, or USD 1.94 per share, against USD 7.7 million, or USD 9.86 per share, in the third quarter of 2025. For the nine months, net loss was USD 40.9 million, or USD 16.77 per share, against USD 26.9 million, or USD 43.82 per share.

Research and development expenses were USD 5.6 million for the quarter, against USD 6.4 million, and USD 18.8 million for the nine months, against USD 22.4 million. General and administrative expenses were USD 3.2 million, against USD 3.7 million, and USD 11.4 million for the nine months, against USD 11.2 million.

Cash and Funding

Cash and cash equivalents were USD 5 million as of September 30, 2026, and the company had approximately 4.1 million shares of common stock outstanding. Management said that, based on its current operating plan, existing cash and cash equivalents together with financing from October are sufficient to fund existing operations into 2027.

Management described PCNSL as one of the rarest and most difficult to treat subtypes of non-Hodgkin lymphoma. It said patients who have failed both frontline therapy and a BTK inhibitor have a poor prognosis, with many proceeding to hospice or best supportive care. It said the updated data in both groups provide further evidence of clinical activity and support the potential for accelerated approval submissions.